Zheng et al. evaluated a novel TPP+ complex with copper as an antimigratory and antiangiogenic drug, showing a decrease in the expression of MMP2 and MMP9, as well as VEGF expression in triple-negative breast cancer model [40]. Here, MMP9 is linked to triple-negative breast carcinoma.